Everyone tries to evaluate the value of this ShareNot easy to evaluate because some informations are missing. However, at the current price and future potential, the share value is very low. Product development is far from being ready for human trials. In practical terms, this means that the previous steps were considered very positive by the FDA, so we must conclude that these drugs work and add to what currently exists. So the next step is to validate, already begun elsewhere, that this is beneficial and adds a plus to medical imaging. These new products, which target different parts of the body to varying degrees, are more effective and enable better analysis of our body's imagery.